THIRD TRI-SERVICE TASK FORCE PROJECT BADGER MEETING

File: 102596_sep96_decls14_0002.txt
Page: 0002
Total Pages: 5

Subject: THIRD TRI-SERVICE TASK FORCE PROJECT BADGER MEETING             

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003202

Folder Title: THIRD TRI-SERVICE TASK FORCE PROJECT BADGER                                                     

Document Number:          1

Folder SEQ  #:          3



                                  I&VO
                                  *JI6%#RE4 UNCLASSIFIED

         SGRD-ZC
         SUBJECT: Third Tri-Service Task Force (Project Badger)
         Meeting @


         3. (U) COL Dangerfield prefaced the meeting by setting two
         parameters: the Task Force will be looking at Best Case and
         Worst Cast scenarios and focusing on numbers of doses, not
         people.

         4.       Anthrax Vaccine:

             a. (S) CDR Paleologo and LTC McKee stated that there was no
          ood information available concerning endemic disease (A) in
                                   According to officials in these
         countries, the disease is not endemic. Efforts to obtain
         serologic prevalence data are in progress. It was agreed not to
         worry about the potential for reaction to immunization in
         indigenous populations having natural immunity and that this is a
         problem to be addressed by policy makers.

             b. (U) Dr. Brandt reported that his survey of potential
         veterinary producers of A revealed that the vaccine is not
         produced in fermenters, but is grown on agar. This eliminates
         those companies from producing a licensed product for human use.

             C. (U) Dr. Johnson-Winegar reported on the status of the
         Market Investigation being done by Sherikoii. A total of
         approximately 150 firms will have been surveyed telephonically.
         From this survey, likely potential producers for A will be
         determined based on three criteria:

                  (1) Whether or not they have functional fermeiiters;

                  (2) If they can produce vaccines under GMP/GLP
         conditions;

                  (3) If they can produce vaccines under at least BL-2
         biocor,tainment conditions.

         She estimates that approximately l@. companies will meet these
         criteria.


             d. (U) Dr. Johnson-Winegar discussed the plan to have a
meeting of prospective participants and pointed out that
         immunization was required for anyone entering the Michigan
         Production Facility. Further, they are interested in working
         with the Task Force, but not in entertaining a large group of
         people. She reminded the group that, although the Army holds the
         patent on the production process, Michigan holds the license.
         Therefore, companies working with Michigan would need to use the
         Michigan Technical Data Package (TDP). The FDA's position on

                                          2
                                    1&1:9!ur.0
                                   @nm%pmlka         UNCLASSIFIED

Document 5 f:/Week-36/BX003202/THIRD TRI-SERVICE TASK FORCE PROJECT BADGER/third tri-service task force project badger meet:10189613544215
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003202
Unit = OTSG
Parent Organization = HSC
Folder Title = THIRD TRI-SERVICE TASK FORCE PROJECT BADGER
Folder Seq # = 3
Subject = THIRD TRI-SERVICE TASK FORCE PROJECT BADGER MEET
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 18-OCT-1996